Contraception in women over 40 years of age

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 7, 2013, Pages 565-573

  Allen, Rebecca H ^a   Cwiak, Carrie A ^b   Kaunitz, Andrew M ^c  

^a BROWN UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

AGE; ARTERIAL THROMBOEMBOLISM; BONE DENSITY; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; FEMALE FERTILITY; FRACTURE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; MENORRHAGIA; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 84876837039     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121280     Document Type: Review

References (82)

1. 2011 census. Ottawa (ON): Statistics Canada. Available: http://www5.statcan. gc.ca/subject-sujet/result-resultat.action ?pid =3867&id=3869&lang=eng&type=OLC&pageNum=1&more=0 (accessed 2012 Dec. 20).
2. Herbenick D, Reece M, Schick V, et al. Sexual behaviors, relationships, and perceived health status among adult women in the United States: results from a national probability sample. J Sex Med 2010;7(Suppl 5):277-90.
3. Trussell J, Guthrie K. Choosing a contraceptive: efficacy, safety, and personal considerations. In: Hatcher RA, Trussell J, Nelson AL, et al. editors. Contraceptive technology. 20th ed. Valley Stream (NY): Ardent Media Inc.; 2011. p. 45-74.
4. Kang BM, Wu TC. Effect of age on intrauterine insemination with frozen donor sperm. Obstet Gynecol 1996;88:93-8.
5. Fertility overview: 2008. Ottawa (ON): Statistics Canada; 2011. Available: www.statcan. gc.ca/pub/91-209-x/2011001/article/11513-eng.htm 3 (accessed 2012 Dec. 20).
6. Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 1995;52:221-2.
7. Cleary-Goldman J, Malone FD, Vidaver J, et al. Impact of maternal age on obstetric outcome. Obstet Gynecol 2005;105:983-90.
8. Joseph KS, Allen AC, Dodds L, et al. The perinatal effects of delayed childbearing. Obstet Gynecol 2005;105:1410-8.
9. Induced abortions in hospitals and clinics, by age group and area of residence of patient, Canada, provinces and territories [Table 106-934]. Ottawa (ON): Statistics Canada; 2009. Available: http://www5.statcan. gc.ca/cansim/pick-choisir?lang=eng &p2=33&id=1069034. (accessed 2012 Dec. 20).
10. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010; Aug: 1-44.
11. Lader D. Contraception and sexual health, 2008-9. London (UK): Office for National Statistics; 2009. Available: www.ons.gov. uk/ons/rel/lifestyles/ contraception-and-sexual-health/2008-09/index.html (accessed 2012 June 26).
12. Black A, Yang Q, Wu Wen S, et al. Contraceptive use among Canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can 2009;31:627-40.
13. Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs and World Health Organization. Family planning: a global handbook for providers. Geneva (Switzerland): World Health Organization; 2011.
14. Cardiovascular disease and use of oral and injectable progestogenonly contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998;57:315-24.
15. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66.
16. Chakhtoura Z, Canonico M, Gompel A, et al. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011;96:1169-74.
17. Chakhtoura Z, Canonico M, Gompel A, et al. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009;40:1059-62.
18. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008;358:1262-70.
19. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36.
20. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism: consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010;36:117-22.
21. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697-706.
22. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
23. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
24. Dinger J, Assmann A, Mohner S, et al. Risk of venous thromboembolism and the use of dienogest-and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:123-9.
25. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142, 475 women-years of observation. Contraception 2007;75:344-54.
26. ACOG practice bulletin no. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107:1453-72.
27. Khader YS, Rice J, John L, et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003;68:11-7.
28. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002;33:1202-8.
29. US Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR Morb Mortal Wkly Rep 2010:59(RR-4):1-86.
30. Hannaford PC, Selvaraj S, Elliott AM, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.
31. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
32. Li CI, Beaber EF, Tang MT, et al. Effect of depo-medroxypro - gesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012;72:2028-35.
33. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007;165:1187-98.
34. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211-7.
35. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67.
36. Isley MM, Kaunitz AM. Update on hormonal contraception and bone density. Rev Endocr Metab Disord 2011;12:93-106.
37. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxy - progesterone acetate and fracture risk. J Clin Endocrinol Metab 2010;95:4909-16.
38. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008;78:459-64.
39. Lopez LM, Chen M, Mullins S, et al. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database Syst Rev 2012;8:CD009849.
40. Lanza L, McQuay LJ, Rothman KJ, et al. Use of depot medroxy - progesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. In press.
41. Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus. Ottawa (ON): the Society; 2004. Available: www.sogc.org/guidelines/index-e.asp#Contraception (accessed 2012 July 25).
42. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimateethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-20.
43. Weiderpass E, Adami HO, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.
44. TM), a low dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139-47.
45. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991;31:66-70.
46. Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011;117:777-87.
47. Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012;85:246-52.
48. National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding [NICE clinical guideline 44]. London (UK): National Institute for Health and Clinical Excellence; 2007.
49. ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010;115:206-18.
50. Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs 2012;72:193-215.
51. Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008;77:22-9.
52. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri-and postmenopausal women. Contraception 2007;75:S155-60.
53. Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104-16.
54. Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95:497-502.
55. Küçük T, Ertan K. Continuous oral or intramuscular medroxy - progesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008;35:57-60.
56. Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil 1985;30:15-28.
57. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-8.
58. Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception 2012;86:606-21.
59. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006;73:445-69.
60. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987;257:796-800.
61. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to metaanalysis. Hum Reprod 1997;12:1851-63.
62. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186-90.
63. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007;75:S60-9.
64. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 2008;371:303-14.
65. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011;105:1436-42.
66. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid hormones and reproductions. Am J Epidemiol 2000;152:233-41.
67. Cibula D, Zikan M, Dusek L, et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011;11:1197-207.
68. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6.
69. ACOG practice bulletin no. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957-66.
70. Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012;119:672-7.
71. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997;71:948-51.
72. Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;84:722-7.
73. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2010;103:1755-9.
74. European Society of Human Reproduction and Embryology. Female contraception over 40. Hum Reprod Update 2009;15:599-612.
75. Beksinska ME, Smit JA, Kleinschmidt I, et al. Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate. Contraception 2003;68:339-43.
76. Juliato CT, Fernandes A, Marchi NM, et al. Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception 2007;76:282-6.
77. Beksinska ME, Smit JA, Kleinschmidt I, et al. Assessing menopausal status in women aged 40-49 using depot-medroxy - progesterone acetate, norethisterone enanthate or combined oral contraception. S Afr Med J 2011;101:131-5.
78. Castracane VD, Gimpel T, Goldzieher JW. When is it safe to switch from oral contraceptives to hormonal replacement therapy? Contraception 1995;52:371-6.
79. Department of Reproductive Health, World Health Organization (WHO). Medical eligibility criteria for contraceptive use. Fourth edition, 2009. Geneva (Switzerland): WHO; 2010.
80. Faculty of Sexual and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists. UK medical eligibility criteria for contraceptive use. London (UK): the Faculty; 2009. Available: www.ffprhc.org.uk/pdfs/UKMEC2009.pdf (accessed 2012 July 27).
81. Hillis SD, Marchbanks PA, Tylor LR, et al. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 1999;93:889-95.
82. Duffy S, Marsh F, Rogerson L, et al. Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005;112:1522-8.